Tigermed reports revenue decline, profit drop in H1 2025

Hangzhou Tigermed Consulting Co. announced its unaudited condensed consolidated interim results for the six months ended June 30, 2025, revealing a total operating revenue of RMB3,250.4 million, a 3.2% decrease from RMB3,358.2 million in the corresponding period of 2024. Gross profit also saw a significant drop of 26.6% to RMB978.0 million from RMB1,333.0 million, with the gross profit margin falling to 30.1% from 39.7%. Net profit attributable to owners of the company declined by 22.2% to RMB383.3 million from RMB492.8 million in H1 2024.

The decline in revenue was primarily attributed to a 10.2% year-over-year slide in the Clinical Trial Solutions (CTS) segment to RMB1,469.5 million, influenced by industry cycles and structural changes, and a decrease in the average unit price of newly signed domestic clinical operations orders. Conversely, the Clinical-Related and Laboratory Services (CRLS) segment saw a modest 3.5% increase in revenue to RMB1,780.9 million. The company resolved not to declare any interim dividend for the six months ended June 30, 2025.

Despite the financial headwinds, Tigermed continued its global expansion, with overseas clinical CRO business revenue and profit growing rapidly. The company also pursued strategic initiatives, including the acquisition of Micron Inc., a Japanese CRO specializing in medical imaging, and ongoing investments in digital and intelligent technologies to enhance operational efficiency.